RBC Europe’s Genetic Technologies Ltd. GENE Stock Holding History

RBC Europe’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4	Closed	-$62	–	1207
2021 Q3	$62	Hold	4	–	–	﹤0.01%	1224
2021 Q2	$85	Hold	4	–	–	﹤0.01%	1213
2021 Q1	$83	Hold	4	–	–	﹤0.01%	1165
2020 Q4	$72	Hold	4	–	–	﹤0.01%	1137
2020 Q3	$69	Hold	4	–	–	﹤0.01%	1084
2020 Q2	$46	Hold	4	–	–	﹤0.01%	1052
2020 Q1	$39	Hold	4	–	–	﹤0.01%	1030
2019 Q4	$40	Hold	4	–	–	﹤0.01%	1040
2019 Q3	$38	Hold	4	–	–	﹤0.01%	1044
2019 Q2	$47	Hold	4	–	–	﹤0.01%	1055
2019 Q1	$71	Hold	4	–	–	﹤0.01%	1065
2018 Q4	$44	Hold	4	–	–	﹤0.01%	1080
2018 Q3	$87	Hold	4	–	–	﹤0.01%	1113
2018 Q2	$79	Hold	4	–	–	﹤0.01%	1127
2018 Q1	$83	Hold	4	–	–	﹤0.01%	1109
2017 Q4	$93	Hold	4	–	–	﹤0.01%	1120
2017 Q3	$68	Buy	+4	New	+$67	﹤0.01%	1126

Other funds holding GENE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RBC Europe's GENE Position: Q4 2021 in Review

RBC Europe sold out of Genetic Technologies Ltd. (GENE) in Q4 2021, closing a stake of 4 shares — an estimated $62 sold.

RBC Europe first reported a position in GENE in Q3 2017 and held it in 17 quarters. The position peaked at $93 in Q4 2017. 13 funds tracked by Wall St. Rank hold GENE as of Q4 2021.

RBC Europe reported no remaining Genetic Technologies Ltd. position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 4 Genetic Technologies Ltd. shares in Q4 2021, an estimated $62.
RBC Europe first reported a position in Genetic Technologies Ltd. in Q3 2017 and held it in 17 quarters.
RBC Europe's Genetic Technologies Ltd. position peaked at $93 in Q4 2017.
13 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.